Barclays PLC Incyte Corp Call Options Transaction History

Barclays PLC

$377 Billion
Q3 2024

Call Options

14 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	BUY	$51.18 - $63.75 $1.54 Million - $1.91 Million	30,000 Added 100.0%	60,000 $3.64 Million
Q1 2024 May 15, 2024	BUY	$56.55 - $66.59 $1.7 Million - $2 Million	30,000 New	30,000 $1.71 Million
Q4 2021 Feb 14, 2022	SELL	$63.34 - $74.11 $671,404 - $785,566	-10,600 Reduced 30.64%	24,000 $1.76 Million
Q1 2020 May 13, 2020	SELL	$63.18 - $85.97 $2.35 Million - $3.2 Million	-37,200 Reduced 51.81%	34,600 $2.53 Million
Q4 2019 Feb 10, 2020	SELL	$73.04 - $95.72 $1.3 Million - $1.7 Million	-17,800 Reduced 19.87%	71,800 $6.27 Million
Q3 2019 Nov 14, 2019	SELL	$72.82 - $86.52 $2.51 Million - $2.98 Million	-34,500 Reduced 27.8%	89,600 $6.65 Million
Q2 2019 Aug 14, 2019	BUY	$73.52 - $88.7 $117,632 - $141,920	1,600 Added 1.31%	124,100 $10.5 Million
Q1 2019 May 15, 2019	SELL	$63.56 - $88.17 $610,176 - $846,432	-9,600 Reduced 7.27%	122,500 $10.5 Million
Q4 2018 Feb 14, 2019	BUY	$58.5 - $69.94 $3.06 Million - $3.66 Million	52,300 Added 65.54%	132,100 $8.4 Million
Q3 2018 Nov 14, 2018	SELL	$61.75 - $74.23 $3 Million - $3.61 Million	-48,600 Reduced 37.85%	79,800 $5.51 Million
Q2 2018 Aug 14, 2018	SELL	$60.85 - $83.98 $12.8 Million - $17.7 Million	-210,200 Reduced 62.08%	128,400 $8.6 Million
Q1 2018 May 15, 2018	BUY	$83.06 - $100.98 $20.8 Million - $25.3 Million	250,200 Added 283.03%	338,600 $28.2 Million
Q4 2017 Feb 14, 2018	SELL	$93.56 - $116.6 $22.9 Million - $28.6 Million	-244,900 Reduced 73.48%	88,400 $8.37 Million
Q3 2017 Nov 14, 2017	BUY	$109.15 - $138.27 $36.4 Million - $46.1 Million	333,300	333,300 $38.9 Million

Others Institutions Holding INCY

# of Institutions

644

Shares Held

186M

Call Options Held

714K

Put Options Held

557K

View Full List

About INCYTE CORP

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

More about INCY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account